# Additional file 11:

## Supplement 18: Grading of Recommendations, Assessment, Development and Evaluations (GRADE) tables for each primary and secondary outcome

Supplement table 7: Summary of findings for PCC versus fresh frozen plasma for reversal of vitamin K antagonists

| Outcomes | Anticipated absolute effects* (95% CI) | | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | Comments |
|---|---|---|---|---|---|---|
| | Risk with FFP | Risk with PCC | | | | |
| All-cause mortality assessed | 10 per 100 | 10 per 100 (3 to 40) | RR 1.05 (0.27 to 4.05) | 262 (2 RCTs) | ⊕⊕◯◯ LOW [a] | Dichotomous unsubjective outcome making incomplete blinding less a concern. |
| Health-related quality of life | Mean HRQOL score 8.21 | Mean HRQOL score on average 1.04 lower (95% CI -0.94 to 3.02) | | 34 (1 RCTs) | ⊕◯◯◯ VERY LOW [a,b] | |
| Serious adverse events | 27 per 100 | 36 per 100 (26 to 51) | RR 1.33 (0.94 to 1.88) | 262 (2 RCTs) | ⊕◯◯◯ VERY LOW [a,b] | |
| Poor functional outcome | 50 per 100 | 53 per 100 (35 to 81) | RR 1.06 (0.70 to 1.62) | 68 (2 RCT) | ⊕◯◯◯ VERY LOW [a,b] | Only evaluated for participants with intracranial haemorrhage |
| Thromboembolic events | 7 per 100 | 11 per 100 (5 to 25) | RR 1.60 (0.70 to 3.61) | 262 (2 RCTs) | ⊕◯◯◯ VERY LOW [a,b] | |
| Allergic reactions | 2 per 100 | 0 per 100 (0 to 5) | RR 0.32 (0.03 to 2.99) | 262 (2 RCTs) | ⊕◯◯◯ VERY LOW [a,b] | |
| Pulmonary oedema | 4 per 100 | 2 per 100 (0 to 10) | RR 0.53 (0.10 to 2.83) | 262 (2 RCTs) | ⊕◯◯◯ VERY LOW [a,b] | |

FFP: Fresh frozen plasma; PCC: Prothrombin complex concentrate; CI: Confidence interval; RR: Risk ratio; HRQOL: Health-related quality of life.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
a. Quality of evidence rated down two levels due to major imprecision.
b. Quality of evidence rated down one level due to major concerns regarding observer-blinding. It is unclear if the observers who detected serious adverse events, thromboembolic events, allergic reactions and pulmonary oedema were blinded to allocation.

Supplement table 8 Summary of findings for PCC plus fresh frozen plasma versus fresh frozen plasma alone for reversal of vitamin K antagonists

| Outcomes | Anticipated absolute effects* (95% CI) | | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | Comments |
|---|---|---|---|---|---|---|
| | Risk with FFP alone | Risk with PCC plus FFP | | | | |
| All-cause mortality | 38 per 100 | 25 per 100 (6 to 100) | RR 0.65 (0.16 to 2.59) | 21 (1 RCT) | ⊕◯◯◯ VERY LOW [a,b] | |
| Health-related quality of life | See comments | See comments | Not estimable | (0 RCTs) | - | No available evidence as the outcome is not evaluated |
| Serious adverse events | 70 per 100 | 29 per 100 (8 to 99) | RR 0.41 (0.12 to 1.41) | 17 (1 RCT) | ⊕◯◯◯ VERY LOW [a,b] | |
| Poor functional outcome | See comments | See comments | Not estimable | (0 RCTs) | - | No available evidence as the outcome is not evaluated |
| Thromboembolic events | 13 per 100 | 6 per 100 (0 to 100) | RR 0.50 (0.02 to 10.34) | 13 (1 RCT) | ⊕◯◯◯ VERY LOW [a,b] | |
| Allergic reactions | See comments | See comments | Not estimable | (0 RCTs) | - | No available evidence as the outcome is not evaluated |
| Pulmonary oedema | 13 per 100 | 6 per 100 (0 to 100) | RR 0.50 (0.02 to 10.34) | 13 (1 RCT) | ⊕◯◯◯ VERY LOW [a,b] | |

FFP: Fresh frozen plasma; PCC: Prothrombin complex concentrate; CI: Confidence interval; RR: Risk ratio
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
a. Quality of evidence rated down two levels due to major concerns about the risk of bias affecting the effect estimate.
b. Quality of evidence rated down two levels due to major imprecision.

Supplement table 9: Summary of findings for PCC plus fresh frozen plasma versus fresh frozen plasma alone for reversal of factor Xa inhibitors

| Outcomes | Anticipated absolute effects* (95% CI) | | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | Comments |
|---|---|---|---|---|---|---|
| | Risk with FFP alone | Risk with PCC | | | | |
| All-cause mortality | 19 per 100 | 15 per 100 (4 to 59) | RR 0.65 (0.16 to 2.59) | 41 (1 RCT) | ⊕◯◯◯ VERY LOW [a,b] | |
| Health-related quality of life | See comments | See comments | Not estimable | (0 RCTs) | - | No available evidence as the outcome is not evaluated |
| Serious adverse events | See comments | See comments | Not estimable | (0 RCTs) | - | No available evidence as the outcome is not evaluated |
| Poor functional outcome | See comments | See comments | Not estimable | (0 RCTs) | - | No available evidence as the outcome is not evaluated |
| Thromboembolic events | 0 per 100 | Unable to estimate | RR 3.14 (0.14 to 72.92) | 41 (1 RCT) | ⊕◯◯◯ VERY LOW [a,b] | |
| Allergic reactions | See comments | See comments | Not estimable | (0 RCTs) | - | No available evidence as the outcome is not evaluated |
| Pulmonary oedema | See comments | See comments | Not estimable | (0 RCTs) | - | No available evidence as the outcome is not evaluated |

FFP: Fresh frozen plasma; PCC: Prothrombin complex concentrate; CI: Confidence interval; RR: Risk ratio
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
a. Quality of evidence rated down two levels due to major concerns about the risk of bias affecting the effect estimate.
b. Quality of evidence rated down two levels due to major imprecision.